Physician profile
Noah M Devicente
NPI 1336237924
$8,646.44
in general payments reported to CMS, 2019-2025
35 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,166 · 2020: $771 · 2021: $1,230 · 2022: $1,386 · 2023: $1,364 · 2024: $1,210 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,070 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,069.54 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,022.40 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,355.63 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $819.69 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $572.20 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Celgene Corporation | $445.57 | 2021-2024 | Zeposia |
| Pfizer INC. | $349.42 | 2019-2025 | |
| Gilead Sciences, INC. | $297.06 | 2019-2025 | |
| Genzyme Corporation | $274.08 | 2022-2025 | |
| Madrigal Pharmaceuticals | $241.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $156.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $132.34 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $116.41 | 2019-2023 | Linzess |
| Ardelyx, INC. | $107.50 | 2022-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $89.76 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $76.73 | 2024-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $68.78 | 2019-2020 | |
| Braintree Laboratories, INC. | $64.10 | 2023-2025 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $48.36 | 2025 | Zenpep |
| Lilly USA, LLC | $47.45 | 2024-2025 | Omvoh |
| Amgen INC. | $41.22 | 2025 | Uplizna |
| Vivus LLC | $36.17 | 2019-2020 | |
| Stryker Corporation | $33.16 | 2025 | Neptune |
| Evoke Pharma, INC. | $31.16 | 2022-2023 | Gimoti |
| Novo Nordisk INC | $28.54 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $25.28 | 2024 | Zeposia |
| Redhill Biopharma INC. | $21.86 | 2021 | |
| Ferring Pharmaceuticals INC. | $19.27 | 2024 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $18.69 | 2023 | Andexxa |
| Shire North American Group INC | $17.67 | 2019 | |
| Exact Sciences Corporation | $16.40 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $16.30 | 2023 | Accrufer |
| Covidien LP | $15.85 | 2019 | |
| Alfasigma USA, INC. | $14.94 | 2020 | |
| Merck Sharp & Dohme LLC | $12.96 | 2021 | |
| Ucb, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Devicente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.